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Abstract
Background:  This study was conducted to determine whether use of hormonal contraceptives is
associated with cervical dysplasia and cancer in a population where there is widespread use of hormonal
contraception and the rates of cervical cancer remain high at 27.5/100,000.
Methods: A case-control study was conducted among women visiting the colposcopy and gynaelogical
clinics at a tertiary referral hospital. Two hundred and thirty six cases CIN I (72), II (59), III (54), cancer
(51) and 102 controls, consented and were interviewed on use of contraceptives using a structured
questionnaire. Logistic regression was used to determine odds ratios (ORs) and 95% confidence intervals
(CIs) associated with use of hormonal contraception in cases and controls and in low and high risk cases.
Recruitment was carried out from 2001–2002.
Results: Contraceptives used were: oral contraceptives – 35%, injections (depot medroxy progesterone
acetate (Depo-provera) – 10%, Intrauterine devices – 2%, combinations of these and tubal ligation – 30%.
23% reported use of 'other' methods, barrier contraceptives or no form of contraception. Barrier
contraceptive use was not significantly different between cases and controls. Current and/or past
exposure to hormonal contraceptives (HC) by use of the pill or injection, alone or in combination with
other methods was significantly higher in the cases. In multivariate analysis with age and number of sexual
partners as co-variates, use of hormonal contraception was associated both with disease, [OR, 1.92 (CI
1.11, 3.34; p = 0.02] and severity of the disease [OR, 2.22 (CI 1.05, 4.66) p = 0.036]. When parity and
alcohol consumption were added to the model, hormonal contraception was no longer significant. The
significant association with high risk disease was retained when the model was controlled for age and
number of sexual partners. Depo-provera use (with age and number of sexual partners as covariates) was
also associated with disease [OR, 2.43 (CI 1.39, 4.57), p = 0.006] and severity of disease [OR 2.51 (1.11,
5.64) p = 0.027]. With parity and alcohol added to this model, depo-provera use retained significance.
Exposure to HC > 4 years conferred more risk for disease and severity of disease.
Conclusion: Hormonal contraception did confer some risk of dysplasia and women using HC should
therefore be encouraged to do regular Pap smear screening.
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Background
The search for links between the use of hormonal contra-
ception or hormone replacement therapy and the devel-
opment of some reproductive system cancers in women
has yielded conflicting results. Thus there is evidence of a
correlation between estrogen and increased risk of breast
cancer while on the other hand, it has been suggested that
use of oral contraceptives for one year or more is protec-
tive against endometrial and ovarian cancers with the pro-
tective effect lasting for at least 10 years [1]. There are
several studies which have reported that hormonal contra-
ception (HC) – pills and injectables – moderately increase
the risk of cervical cancer as well as being a risk for all
stages of cervical cancer [2-8] particularly in human pap-
illoma virus (HPV)-positive women thus suggesting that
oral contraceptives may act as a promoter for HPV-
induced carcinogenesis [4,5].
The inconsistent reports of an association between hor-
monal contraception and cervical dysplasia and cancer
may be related, in part, to confounding risk factors that
include sexual and lifestyle behaviours [2,3]. The causal
link between HPV and cervical dysplasia and cancer is
now generally accepted [9-13]. In addition to any direct
effect of HC on the development of cervical dysplasia,
either as an initiator or promoter of carcinogenesis [4,5],
the use of hormonal contraceptives could result in women
indulging in more unprotected sexual activity putting
them at more risk of HPV and other STI infections and
their sequelae.
Since the 1960s, use of HC for family planning has been
actively encouraged in Jamaica. In addition to pills, Depot
medroxy progesterone acetate (DMPA) injections and
lovonorgestrel implants are available. Data from a Repro-
ductive Health Survey by the National Family Planning
Board (2002) showed that in addition to a doubling in
the use of condoms, since 1989, there has been a 48%
increase in the use of injectables (22.7% vs 33.6%) in
women reporting ever use of contraception. Over the
period, pill use rose from 47.6% to 56.5% [14].
Given the high incidence of cervical dysplasia [15] and
that cervical cancer rates remain high at 27.5/100,000
[16], we looked at whether HC use in the population was
a factor in the development of cervical dysplasia and can-
cer.
Methods
Study design and subjects
Ethical approval was obtained from the University Hospi-
tal of the West Indies (UHWI) Ethical Review board. Both
cases and the comparison group were recruited at the
UHWI between April 2001–August 2002. Cases were
enrolled from twice weekly conducted colposcopy clinics
while women in the comparison group were recruited
from weekly gynaecology clinics at the same hospital.
Both clinics receive referrals from primary care clinics,
hospitals and private practitioners. Consecutive women
were invited to participate in the study.
Cases
Women with abnormal Pap smears who had been
referred to the Colposcopy clinic and had a diagnosis that
was confirmed by colposcopic biopsy histology served as
the sampling frame. Cases were identified from the clinic
registry where they were documented according to the
degree of cervical intraepithelial neoplasia (CIN) as CIN-
I, CIN-II, CIN-III and cervical cancer.
Comparison group
Women attending routine gynaecological clinics who had
normal Pap smears were regarded to be disease-free and
served as the comparison group.
Table 1: Characteristics of women with cervical dysplasia (n = 240) and the comparison group (n = 102). and their patterns of 
contraceptive use.
Variable Cases Comparison group
Age (years, mean ± SD) 39.1 ± 11.8 38.1 ± 10.0
Reproductive & lifestyle factors:
Number of lifetime sex partners (mean ± SD) 4.9 ± 2.1 4.6 ± 2.9
Parity (mean ± SD) 2.8 ± 2.1 2.1 ± 2.4
Regular use of pap smear (%) 32.3 47.7
Consuming alcohol (%) 21.1 10.4
Contraceptive use % (n):a
None 16.6 (40) 28.8 (29)
Pills 30.4 (73) 34.3 (35)
Injections 11.3 (27) 5.8 (6)
Intra Uterine Device (IUD) 1.7 (4) 2.0 (2)
Combinations – Pills, Injections, IUD 26.3 (63) 13.7 (14)
Combinations – Pills, Injections, tubal ligation 4.2 (10) 7.8 (8)
Other 0.4 (1) 1.0 (1)
a 22 cases and 7 subjects from the comparison group missing.BMC Women's Health 2008, 8:9 http://www.biomedcentral.com/1472-6874/8/9
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The study population consisted of CIN-I (n = 72), CIN-II
(n = 59), CIN-III (n = 54), cervical cancer (n = 51) and
controls (n = 102). When grouped according to severity of
disease using the Bethesda classification, there were 72
with low grade lesions (LGSIL) and 164 with high grade
lesions (HGSIL). Informed consent was sought after an
explanation of the study and those who agreed were asked
to sign a consent form. Confidentiality and anonymity
were assured before they were interviewed using a struc-
tured questionnaire by a single female interviewer. Data
on drinking, smoking and other behavioural variables
and sexual characteristics were collected. Participation
rates among cases and the comparison group were 72%
and 60% respectively.
Exclusion criteria
The following persons were excluded from the investiga-
tion: women who were pregnant, had hysterectomies or
were previously diagnosed with adenocarcinoma.
Statistical Analyses
Differences between cases and the comparison group were
examined by the t-test and χ2 as appropriate. Logistic
regression was used to determine the association of repro-
ductive and lifestyle factors with disease (presence and
severity). Odds Ratios (OR) and confidence intervals (CI)
are presented. Analyses were performed using the SPSS
software (version 12.0). Statistical significance was
achieved when p < 0.05.
Results
Table 1 shows the characteristics of women with cervical
dysplasia and the comparison group and their pattern of
contraceptive use. They were of similar age, had about the
same number of sex partners but the cases had had more
children, had used Pap smear screening more infrequently
and were more likely to have consumed alcohol. The
methods of contraception used by women in this study
were: oral contraceptives (OC) – 35%, DMPA injections –
10%, Intrauterine devices (IUD) – 2%, combinations of
OC, DMPA, IUD, and tubal ligation – 30%. The remain-
ing 23% reported use of 'other' methods, barrier contra-
ceptives or no form of contraception. The majority of the
women did not use barrier contraceptives; cases 80.5%
and comparison group 68.8%. Non – use of barrier con-
traceptives was not associated with development of dis-
ease [OR, 0.63 (CI 0.37, 1.08; p = 0.094].
Current and/or past exposure to hormonal contraceptives
by use of the pill or injection, alone or in combination
with other methods was significantly higher in the cases
(79.4%) compared to the comparison group (67.4%) p =
0.023. There was also a significant difference between
women classified as high risk (HGSIL) (82.9%) and low
risk LGSIL (69.8%) (Bethesda classification) p = 0.032
(Table 2). When women who had used DMPA were com-
pared to women who had never used this method, there
were also significant differences in presence of and sever-
ity of disease (p = 0.003 and 0.012) respectively.
With age and number of sexual partners as co-variates, use
of HC was associated both with presence of disease [OR
1.92 (CI 1.11, 3.34); p = 0.02] and the severity of the dis-
ease, [OR 2.22 (CI 1.05, 4.66); p = 0.036 ]. When parity
and alcohol consumption (predictors of disease), were
added to the model, HC use was no longer significant
[OR, 1.59, (CI 0.87, 2.82); p 0.13]. Significant associa-
tions were observed for high risk disease when HC, age
and number of sexual partners (predictor for severity of
disease) were included in the model, [OR = 2.22, (CI 1.05,
4.66) p = 0.036] (Table 3). When use of barrier contracep-
tives was added to the model, the association of disease
and the severity of disease with use of HC was virtually
unchanged, [OR,1.95 (CI 1.13, 3.38); p = 0.017] and [OR,
2.21 (CI 1.08, 4.53); p = 0.031], respectively.
Of the 236 women who had used HC, 128 (57.2%)
reported ever use of DMPA. When these women were
compared to those who had never used HC, the percent-
age of cases who were ever users of DMPA was signifi-
cantly greater than the controls (χ2 = 8.99, p = 0.03). There
were also more DMPA users among the HSIL compared to
Table 2: Percentage of women exposed to hormonal contraceptives (HC) and depot medroxy progesterone acetate (DMPA) by 
presence and severity of disease
Presence of disease Severity of disease
Contraceptive used Comparison
Cases Group p value HGSILa LGSILb p value
HCc 79.4 67.4 0.023 82.9 69.8 0.032
DMPAd 69.0 46.7 0.003 75.0 53.7 0.012
a LGSIL – low risk lesions
b HGSIL – high risk lesions
c HC = ever use of hormonal contraceptives by use of the pill, injection or in combination with other methods.
d DMPA = women who reported ever use of injections alone or in combination with other methods.BMC Women's Health 2008, 8:9 http://www.biomedcentral.com/1472-6874/8/9
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the LSIL (χ2 = 6.26, p = 0.012). The ORs also shown in
Table 3, were slightly higher than those for use of HC, e.g.
2.43 vs 1.92 and 2.51 vs 2.22. DMPA use did retain signif-
icance when parity and use of alcohol were included in
the model. The effect of DMPA on severity of disease was
retained when lifetime sexual partners were added to the
model.
Length of exposure to HC varied from one week to greater
than ten years with 47.5% having used HC for >4 years. Of
the controls, 18.2% and 8.3% had been exposed to HC for
<4 years and >4 years respectively while among the cases,
percentages exposed were 34.3% and 39.3% respectively.
These differences were significant, p = 0.002. Among cases
there was also a significant association with high risk dis-
ease, p = 0.005. With adjustment for age and number of
sexual partners, duration of exposure showed a significant
association with disease [OR, 3.56 (CI 1.81, 7.00; p =
0.001)] and severity of disease [OR 4.43 (1.43, 5.02); p =
0.017] (Table 3). There were no data available on length
of use of DMPA only.
Discussion
In this population, current and/or past exposure to HC by
use of the pill or injection, alone or in combination with
other methods, was significantly higher in cases. Analysis
indicates an independent role for HC use especially as it
relates to the severity of disease whilst presence of the dis-
ease as a result of HC use was modified by the factors that
were found to predict the disease. The majority of the
women, cases and controls, did not use barrier contracep-
tives and so were at risk of multiple infections, inclusive
of HPV. The duration of the exposure was important such
that women who had been using HC for more than four
years were at greater risk for both disease and severity of
disease. The authors of an earlier study of carcinoma-in -
situ (CIS) patients suggested that risk of CIS may be con-
fined to long term users [17].
Several studies have contributed to the present under-
standing of the relationship between the use of HC and
disease. The International Agency for Research on Cancer
(IARC) pooled data from eight studies of invasive cancer
and two of carcinoma in situ in HPV positive cases and
found that risk increased significantly with parity [18].
Women who used HC for less than 5 years were not at
increased risk but risk became apparent after 10 years
[18]. Results from the WHO collaborative Study of Neo-
plasia and Steroid Contraceptives showed that there was a
slight risk for ever-users that increased with duration of >
4 years [7]. Similar findings were reported by the Oxford
Family Planning Association contraceptive study [19,20].
Based on the most recent evaluation of several studies, the
IARC has concluded that HC can be classified as carcino-
genic to the cervix as well as to the breast[21]. Given that
HPV infection is now considered the major factor in the
development of cervical cancer, it would seem that HC
may be acting as an enhancer of neoplastic growth. Since
estrogen is known to have trophic effects consistent expo-
sure to above normal levels could result in this growth.
Some investigators found that women with higher levels
of estrogen receptor transcripts were significantly more
likely to have cervical HPV infection and that estrogen
binds to specific DNA sequences within transcriptional
regulatory regions on the HPV DNA[22]. It has also been
shown that HPV-18 E6 and E7 proteins directly interacted
with the estrogen receptor[23]. Cervical ectopy, common
in women using HC, [24] could also increase susceptibil-
ity to HPV infection. The fact that the association with HC
and DMPA exposure is modified by lifestyle covariates
Table 3: Odds Ratios and Confidence Intervals for hormonal contraceptive effect (HC), medroxy progesterone acetate (DMPA) effect, 
>4 year HC use on (a). presence and (b). severity of disease.
Presence of disease Severity of disease
Model OR (CI) OR CI
Hormonal contraceptive use:
Never used 1.0 (reference) 1.0 (reference)
HCa 1.92 (1.11, 3.34) 2.22 (1.05, 4.66)
HC + parity + alcohol intake ab 1.59 (0.87, 2.82)
DMPA use:
Never used 1.0 (reference) 1.0 (reference)
DMPAa 2.43 (1.39, 4.57) 2.51 (1.11, 5.64)
DMPA + parity + alcohol intakeab 2.48 (1.30, 4.74)
Length of exposure:a
Never used 1.0 (reference) 1.0 (reference)
1–4 years 1.47 (0.80, 2.71) 1.68 (0.73, 3.89)
>4 years HC use 3.56 (1.81, 7.00) 4.43 (1.84, 10.67)
a Models were adjusted for age and number of sexual partners.
ab Variables entered; age and number of sex partners, variables offered: parity and alcohol consumption.BMC Women's Health 2008, 8:9 http://www.biomedcentral.com/1472-6874/8/9
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suggests that HC, usually associated with less use of bar-
rier protection during sexual contact (exposure to other
infections), as well as direct effects of the HC could
explain the associations. We have found that bacterial
vaginosis is a risk factor for HPV infection (unpublished
observations).
Whereas we did not have data on HPV infection in the
comparison group in this study, our findings of high rates
of HPV infection among healthy pregnant and non preg-
nant women in Jamaica [25], suggests that the controls in
this study were very likely to be infected with HPV.
The data indicates that fewer than 50% of the women
underwent regular screening by Pap smear, while in a
smaller study of university students only 27% reported
screening [26]. Since hormonal contraception is widely
used and its use in our population is in fact encouraged, it
is imperative that such women be educated and encour-
aged to do regular Pap smears to enhance early detection.
Conclusion
Use of HC confers some risk of dysplasia which may be
modified/confounded by use of barrier contraceptives,
increased number of sexual partners, increased number of
biological fathers, parity and alcohol consumption. Given
the wide use of HC, regular Pap smear screening should be
encouraged.
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